AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss
AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.